{"id":"eszopiclone-2-mg-non-elderly","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Somnolence/Drowsiness"},{"rate":"5-10","effect":"Unpleasant taste"},{"rate":"5","effect":"Anxiety"},{"rate":"5","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. By enhancing the effect of the inhibitory neurotransmitter GABA, it increases neuronal hyperpolarization and reduces neuronal excitability, leading to sedation and sleep initiation. It is selective for GABA-A receptors over other CNS targets, which contributes to its favorable safety profile compared to older benzodiazepines.","oneSentence":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:40.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep initiation and maintenance) in non-elderly adults"}]},"trialDetails":[{"nctId":"NCT02455271","phase":"","title":"Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":438},{"nctId":"NCT02452684","phase":"","title":"Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":4876},{"nctId":"NCT00770692","phase":"PHASE3","title":"A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Insomnia","enrollment":369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SEP-190"],"phase":"phase_3","status":"active","brandName":"Eszopiclone 2 mg- Non-elderly","genericName":"Eszopiclone 2 mg- Non-elderly","companyName":"Eisai Co., Ltd.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep. Used for Insomnia (sleep initiation and maintenance) in non-elderly adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}